LIFE News and Press, aTyr Pharma Inc. From 03/19/20

SAN DIEGO, March 19, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report fourth quarter and full year 2020 financial r...

SAN DIEGO, March 17, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced the appointment of Arthur M. Mercurio, Ph.D. as a scientific advi...

SAN DIEGO, March 10, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced the underwriters of its previously announced public offering of c...

Under Priority Review and Breakthrough Therapy status, the FDA approves privately held Boehringer Ingelheim's Ofev (nintedanib) oral capsules for the treatment of patients with chronic fibrosing (scarring) interstitial lung diseases (ILD) with a progressive phenotype (trait). More news o...

This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 02/13/2020. Please visit our Tracking Ole Andreas Halvorsen&#...

Paper highlights the essential role that histidyl tRNA synthetase (HARS) plays in immune responses in a broad range of inflammatory disease states Lead therapeutic candidate, ATYR1923, being evaluated in a Phase 1b/2a trial in patients with pulmonary sarcoidosis SAN DIEGO, Feb. 27...

aTyr Pharma (NASDAQ: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, has closed an underwritten public offering of 4,235,294 shares of its common stock. According to the update, the shares were each sold a...

SAN DIEGO, Feb. 06, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced the pricing of an underwritten public offering of 4,235,294 shares...

Gainers: Seneca Biopharma (NASDAQ: SNCA ) +126% . More news on: Seneca Biopharma, Inc., iMedia Brands, Inc., Aptinyx Inc., Stocks on the move, , Read more ...

Aethlon Medical (NASDAQ: AEMD )  -28%  on pricing equity offering. More news on: Aethlon Medical, Inc., aTyr Pharma, Inc., DURECT Corporation, Stocks on the move, , Read more ...